Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSE-127 in Moderate to Severe Active Ulcerative Colitis
NCT04882007Phase 2Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of lusvertikimab in ulcerative colitis (UC), sponsored by OSE Immunotherapeutics. Started Oct 2020; status: completed.
02
Drugs
lusvertikimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04882007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04882007.